As a former adviser to several federal entities, FDA Commissioner Scott Gottlieb, MD was familiar with public service before he assumed his current position in early 2017.
But he also had ties to the pharmaceutical industry and, thus, not all were convinced he would make good on his promises to change the status quo on drug prices, opioids and tobacco.
“I was concerned that he would be overly deferential to industry interests,” C. Michael White, PharmD, FCP, FCCP, of the department of pharmacy practice at the University of Connecticut, told Healio Primary Care Today.
Arthur Caplan,

Source link